Trial Profile
Dose Escalation and Pharmacodynamic Study of Intravenous Administration of REOLYSIN, a Live Replication Competent RNA Virus in Patients with Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jun 2009
Price :
$35
*
At a glance
- Drugs Pelareorep (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 01 Jun 2009 Results presented at American Society of Clinical Oncology (ASCO) 2009 annual meeting, according to an Oncolytics Biotech media release.
- 14 Jun 2007 New trial record.